-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Keyou Pharmaceutical Showcases Core Products at CPHI Japan 2026, Strengthening Its Market Presence in Japan and Advancing Its Globalization Strategy
Publish Time:
2026-04-23
From April 21 to 23, CPHI Japan 2026 was grandly held in Tokyo, Japan. Shandong Keyuan Pharmaceutical Co.,Ltd. (stock code: 301281.SZ) showcased its products in key therapeutic areas such as antidiabetic, cardiovascular, and anesthetic drugs at this exhibition, comprehensively demonstrating the company’s robust R&D and manufacturing capabilities as well as its internationally recognized achievements in the field of chemical APIs, while actively connecting with global pharmaceutical industry resources.
From April 21 to 23, CPHI Japan 2026 was grandly held in Tokyo, Japan. Shandong Keyuan Pharmaceutical Co.,Ltd. (stock code: 301281.SZ) showcased its products in key therapeutic areas such as antidiabetic, cardiovascular, and anesthetic drugs at this exhibition, comprehensively demonstrating the company’s robust R&D and manufacturing capabilities as well as its internationally recognized achievements in the field of chemical APIs, while actively connecting with global pharmaceutical industry resources.
At this exhibition, Keyuan Pharmaceutical aligned itself with the event’s core mission of “innovating new drug development and meeting the needs of the entire industry chain,” with a particular focus on showcasing its flagship products, including isosorbide mononitrate, metformin hydrochloride, ropivacaine hydrochloride, and methylcobalamin. Among these, isosorbide mononitrate stands out as the company’s core product for its deep penetration into the Japanese market, having maintained stable partnerships with local customers for more than a decade. Thanks to its consistent product quality, stringent compliance controls, and efficient supply capabilities, it has earned high recognition and unwavering trust from Japanese clients.
At the exhibition, a portfolio of products that have successfully obtained official pharmaceutical regulatory approvals from multiple jurisdictions—including the EU’s CE marking, the U.S. FDA, Japan’s PMDA, and South Korea’s MFDS—drew keen interest from procurement executives, R&D leaders, and industry experts from pharmaceutical companies across Japan and the Asia-Pacific region, who stopped by to engage in meaningful exchanges. Li Lei, Vice President of Marketing, led his team in providing visiting clients with a comprehensive overview of the products’ production capacity, quality control systems, and international certification status, while also holding in-depth discussions on potential collaboration opportunities.
As a publicly listed company with more than two decades of deep expertise in the active pharmaceutical ingredient (API) sector, Keyuan Pharmaceutical has consistently adhered to a “globalization of operations” strategy. Leveraging a dual R&D engine—self-driven innovation combined with external collaboration—the company has established a fully integrated, end-to-end value chain spanning research and development, manufacturing, and sales. The company operates provincial-level enterprise technology centers and postdoctoral innovation practice bases, among other R&D platforms, and collaborates closely with leading institutions to accelerate the commercialization of cutting-edge technologies. In addition, it has built three state-of-the-art digital and intelligent manufacturing hubs to ensure superior product quality. This exhibition serves as a crucial platform for the company to showcase its robust capabilities, while also representing a pivotal step toward deeper integration into the global pharmaceutical supply chain and closer engagement with high-end international markets.
Against the backdrop of the accelerating reshaping of the global pharmaceutical supply chain, Keyuan Pharmaceutical will continue to increase its investment in R&D innovation and international expansion. Driven by technological innovation, the company will deepen its localization efforts, strengthen international collaboration, and promote the global reach of China’s high-end, Made-in-China active pharmaceutical ingredients, thereby providing higher-quality pharmaceutical products and services to patients worldwide.
Latest News
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline